Sfoglia per AUTORE
NIGRO O
Collezione AOU Novara
Items : 6
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2023 Jul 14;29(14):2714-2724. doi: 10.1158/1078-0432.CCR-22-3116.
2023
AOU Novara
Cortellini A; D'Alessio A; Cleary S; Buti S; Bersanelli M; Bordi P; Tonini G; Vincenzi B; Tucci M; Russo A; Pantano F; Russano M; Stucci LS; Sergi MC; Falconi M; Zarzana MA; Santini D; Spagnolo F; Tanda ET; Rastelli F; Giorgi FC; Pergolesi F; Giusti R; Filetti M; Lo Bianco F; Marchetti P; Botticelli A; Gelibter A; Siringo M; et alii...
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.
2022
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara
Russo A; Russano M; Tiseo M; Porzio G; Ficorella C; Addeo A; Friedlaender A; Banna GL; Passiglia F; Spinelli GP; Metro G; Migliorino MR; Zoratto F; Ricciardi S; Mansueto G; Pecci F; Di Marino P; Gori S; De Tursi M; Tuzi A; Della Gravara L; Rastelli F; Macerelli M; Gelibter A; Chiari R; Marchetti P; Antonuzzo L; Mazzoni F; Genova C; et alii...
Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
2021
AOU San Luigi di Orbassano
AO Ordine Mauriziano
AOU Novara
Russo A; Adamo V; Metro G; De Filippis M; Simona C; Natalizio S; Migliorino MR; Ricciardi S; Landi L; Minuti G; Buti S; Nigro O; Cantini L; Russano M; Citarella F; Bracarda S; Filetti M; Zoratto F; Mansueto G; De Tursi M; Gori S; Rocco D; Chiari R; Rastelli F; Gelibter A; Targato G; Signorelli D; De Toma A; Mazzoni F; et alii...
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. in Journal of translational medicine / J Transl Med. 2021 Jun 24;19(1):270. doi: 10.1186/s12967-021-02937-9.
2021
AOU Novara
Santini D; Zeppola T; Russano M; Citarella F; Anesi C; Buti S; Tucci M; Russo A; Sergi MC; Adamo V; Stucci LS; Bersanelli M; Mazzaschi G; Spagnolo F; Rastelli F; Giorgi FC; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Siringo M; Ferrari M; Marconcini R; Vitale MG; Nicolardi L; Chiari R; Ghidini M; Nigro O; et alii...
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara
Cannita K; Porzio G; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Russo A; Adamo V; Metro G; Olmetto E; Tabbò F; Migliorino MR; Ricciardi S; Landi L; Minuti G; Tuzi A; Bisonni R; Follador A; Siringo M; Gelibter A; Signorelli D; De Toma A; Garassino MC; Mazzoni F; Russano M; Citarella F; Filetti M; Zoratto F; Mansueto G; et alii...
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. in Journal for immunotherapy of cancer / J Immunother Cancer. 2021 Apr;9(4):e002421. doi: 10.1136/jitc-2021-002421.
2021
AOU San Luigi di Orbassano
ASL Città di Torino
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara
Russo A; Adamo V; Metro G; Bironzo P; Passiglia F; Migliorino MR; Ricciardi S; Landi L; Minuti G; Bordi P; Tuzi A; Cantini L; Russano M; Citarella F; Santini D; Filetti M; Zoratto F; Mansueto G; Di Marino P; Grassadonia A; Michele T; Inno A; Della Gravara L; Rocco D; Chiari R; Rastelli F; Macerelli M; Marchetti P; Siringo M; et alii...